T1	intervention 19 42	dose-dense FEC regimens
T2	outcome 1709 1760	serious adverse events (vomiting and throat oedema)
T3	cv-bin-abs 1675 1678	one
T4	outcome 1576 1630	increases in liver enzymes and gastrointestinal events
T6	outcome 1388 1423	Grade 3-4 haematological toxicities
T7	cv-bin-abs 1441 1444	two
T8	outcome 1377 1386	diarrhoea
T9	iv-bin-percent 1154 1158	4.1%
T10	cv-bin-percent 1179 1183	9.8%
T11	outcome 970 1036	proportion of subjects receiving > or =85% relative dose intensity
T12	eligibility 94 127	patients with early breast cancer
T14	control 764 771	FEC(90)
T15	iv-bin-percent 1057 1060	96%
T16	cv-bin-abs 1065 1068	88%
T17	intervention-participants 1131 1134	147
T18	control-participants 1187 1190	143
T20	outcome 1199 1221	infusions were delayed
T5	outcome 1488 1521	incidences of febrile neutropenia
T19	cv-bin-abs 1310 1313	One
